This trial is testing a new cancer treatment that uses molecular targeted therapy in combination with adoptive cell therapy. The goal is to find the maximum tolerated dose and to evaluate the safety and feasibility of this new treatment.
1 Primary · 5 Secondary · Reporting Duration: 7 years
24 Total Participants · 2 Treatment Groups
Primary Treatment: Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) · No Placebo Group · Phase 1
Age 1 - 30 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: